DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Harrison C, Kiladjian JJ, Al-Ali HK. , et al.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med 2012;
366 (09) 787-798
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.